531681 — Amerise Biosciences Income Statement
0.000.00%
Last trade - 00:00
- IN₹40.30m
- IN₹41.25m
- 16
- 43
- 36
- 17
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 90.1 | 0 |
Cost of Revenue | |||||
Gross Profit | -11.6 | 0 | 0 | 0.933 | 0 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 11.8 | 1.5 | 1.68 | 90.3 | 1.27 |
Operating Profit | -11.8 | -1.5 | -1.68 | -0.203 | -1.27 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 0.041 | -1.49 | -3.37 | 5.49 | -1.19 |
Provision for Income Taxes | |||||
Net Income After Taxes | 0.041 | -1.49 | -3.37 | 5.49 | -1.19 |
Net Income Before Extraordinary Items | |||||
Net Income | 0.041 | -1.49 | -3.37 | 5.49 | -1.19 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.041 | -1.49 | -3.37 | 5.49 | -1.19 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.001 | -0.023 | -0.051 | 0.083 | -0.018 |